Getting personal: the promises and pitfalls of personalized medicine

Translational Research

Volumn 154, Issue 6, 2009, Pages 269-271

  Laurence, Jeffrey ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; INTERLEUKIN 28; MENADIONE EPOXIDE; MORPHINE; OMEPRAZOLE; OXIDOREDUCTASE; PRASUGREL; RIBAVIRIN; TAMOXIFEN; VITAMIN K GROUP; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CHROMOSOME 19; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; GENOMICS; GENOTYPE; HEALTH CARE PRACTICE; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL INFORMATION; MEDICAL RESEARCH; MEDICINE; MOLECULAR BIOLOGY; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 70449493192     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.09.010     Document Type: Note

References (18)

1. Abrahams E. Personalized medicine realizing its promise. Gen Eng Biotech News 29 15 (2009) 70-73
2. Laurence J. No more boring science, no more waste in clinical trials. Transl Res 153 (2009) 1-3
3. Peddicord D. Access to global populations speeds trials. Gen Eng Biotech News 29 15 (2009) 18
4. Khoury M. A conversation about personal genomic tests. NCI Cancer Bull 6 (2009) 5-6
5. Goldstein D.B. Common genetic variation and human traits. N Engl J Med 360 (2009) 1696-1698
6. Wade N. Study of genes and diseases at an impasse (2009), New York Times p. A1
7. Iadonato S.P., and Katze M.G. Hepatitis C gets personal. Nature 461 (2009) 357-358
8. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009) 399-402
9. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Gen 41 (2009) 1100-1104
10. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis. C. Nature Gen 41 (2009) 1105-1109
11. Jones D. Steps on the road to personalized medicine. Nature Rev Drug Disc 6 (2007) 770-771
12. Rosove M.H., and Grody W.W. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 151 (2009) 270-273
13. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 (2007) 2563-2570
14. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113 (2009) 784-792
15. Roden D.M., and Stein C.M. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 119 (2009) 2127-2130
16. O'Donoghue M.L., Braunwald E., Antman E.M., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 374 (2009) 989-997
17. Pollack A. Patient's DNA may be signal to tailor drugs (2008), New York Times p. A1
18. Garber K. Trial offers early test case for personalized medicine. J Natl Cancer Inst 101 (2009) 136-138